Dyne Therapeutics (DYN) Stock Price, News & Analysis

Company Overview

Dyne Therapeutics is a clinical-stage biotechnology company focused on the development of precision genetic therapies for serious rare neuromuscular diseases. Established in 2019 as a spin-out from Flagship Pioneering, Dyne leverages proprietary delivery technology to enhance the uptake and targeting of oligonucleotide therapeutics. The company’s mission is to create potentially transformative treatments for patients affected by diseases such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and limb-girdle muscular dystrophies, which historically have had limited therapeutic options.

At the core of Dyne’s strategy is its FORCE (Facilitated Oligonucleotide Chemistries and Enhanced Delivery) platform, designed to improve cellular delivery of oligonucleotides across muscle and other challenging tissues. This platform enables the company to optimize stability, tissue specificity, and pharmacological activity of its candidates. Dyne’s lead program, DYST-ON, is a next-generation antisense oligonucleotide for Duchenne muscular dystrophy currently in clinical development, while MYO-101 for myotonic dystrophy type 1 and additional programs targeting various limb-girdle muscular dystrophy subtypes are advancing in preclinical and early clinical stages.

Dyne maintains collaborations with several major pharmaceutical and biotechnology partners to broaden its research capabilities and accelerate clinical development. The company has entered strategic alliances aimed at co-developing next-generation oligonucleotide drugs, drawing upon the global expertise of industry leaders. These partnerships are intended to leverage shared resources for manufacturing, regulatory planning, and commercialization, positioning Dyne to bring potential therapies to patients more efficiently.

Headquartered in Cambridge, Massachusetts, Dyne Therapeutics serves both U.S. and international patient communities through ongoing clinical trials and research activities. Under the leadership of Founder and Chief Executive Officer Edward Kaye, Ph.D., the management team combines deep expertise in molecular biology, drug delivery, and rare disease clinical development. With a commitment to scientific innovation and patient-centric research, Dyne is advancing a pipeline of differentiated therapies that aim to address unmet needs in neuromuscular disease treatment.

Key Stats

• Today's Range: $8.06 to $8.84
• 50-Day Range: $8.18 to $14.78
• 52-Week Range: $6.36 to $47.45
• Volume: 3.67 million shs
• Average Volume: 1.82 million shs
• Market Capitalization: $929.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.13
• Consensus Rating: Buy

Dyne Therapeutics Stock Analysis - MarketRank™

Dyne Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 240th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Dyne Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyne Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyne Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyne Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

21.13% of the float of Dyne Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dyne Therapeutics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Dyne Therapeutics has recently decreased by 19.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyne Therapeutics does not currently pay a dividend.

Dividend Growth

Dyne Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.13% of the float of Dyne Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dyne Therapeutics has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Dyne Therapeutics has recently decreased by 19.23%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.32

News Sentiment

Dyne Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Dyne Therapeutics this week, compared to 7 articles on an average week.

Search Interest

2 people have searched for DYN on MarketBeat in the last 30 days.

MarketBeat Follows

6 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dyne Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.14% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DYN Stock Analysis - Frequently Asked Questions

How have DYN shares performed this year?

Dyne Therapeutics' stock was trading at $23.56 at the beginning of 2025. Since then, DYN shares have decreased by 65.3% and is now trading at $8.18.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its earnings results on Thursday, May, 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by $0.17.

When did Dyne Therapeutics IPO?

Dyne Therapeutics (DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dyne Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DYN
• Previous Symbol: NYSE:DYN
• CIK: 1818794
• Web: www.dyne-tx.com
• Phone: 781-786-8230
• Fax: 781-786-8866
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $41.13
• High Stock Price Target: $66.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +402.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$317.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -52.83%
• Return on Assets: -48.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.35
• Quick Ratio: 20.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.19 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 113,667,000
• Free Float: 90,058,000
• Market Cap: $929.80 million
• Optionable: Optionable
• Beta: 1.08